Research
Hormonal
GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.
GLP-1RAs may be considered for patients with T2D who also have renal concerns, particularly regarding macroalbuminuria.
StrongQualifiesmedium confidence
In addition, GLP-1RAs may have renal benefits driven by new-onset macroalbuminuria.
Why this rating
Based on findings from large-scale studies.
Source
Understanding the place for <scp>GLP‐1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Christine R. Andreasen et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14500
reviewCited 36×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →